Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

g of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with U.S. and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and other genetic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward-looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward-looking statements. Important factors that may cause actual results to differ materially from those indicated by forward-looking statements include, among others:

-- the potential that results of clinical or preclinical studies indicate

that product candidates are unsafe or ineffective,

-- our dependence on third parties in the conduct of our clinical studies,

-- a change in strategy by our collaboration partners,

-- delays or failure to achieve final agreement with regulatory

authorities on the design of phase 3 program for Amigal and the

regulatory pathway for approval of Amigal,

-- delays or failure to achieve regulatory approvals for our products,

-- risks of relying on third party manufacturers for the supply of our

product candidates,

-- our or licensors' inability to obtain, maintain and successfully<
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... Research and Markets  has announced the ... by Application, Geography - Global Analysis and Forecast (2014 ... Organic electronics, also called as polymer electronics or ... deals with small conductive molecules and electrically conductive polymers. ... polymers are carbon based, made using synthetic strategies developed ...
(Date:10/20/2014)... 20, 2014 The report “Pharmacy ... Systems, Packaging and Labeling Systems, Table-top Counters) by ... Global Forecasts & Trends to 2019” analyzes and ... in North America, Europe, Asia-Pacific, and the Rest ... tables and 30 figures spread through 300 pages ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... ChemAxon, a software,solutions provider for cheminformatics, today announced ... for working with chemical and,other data on local ... and form building, relational data support, advanced query ... the vast,majority of functionality and is free for ...
... CITY, Calif., Aug. 21 Codexis, Inc., a private,biotechnology ... the new position of Vice President and Managing Director ... first,facility in Asia. Dr. Daussmann will report to Alan ... to name Dr. Daussmann to this important new,position on ...
... to Increase Efficiency, MINNEAPOLIS, Aug. 21 ... a leading provider of enterprise-wide advanced,visualization and ... its,next generation enterprise-wide advanced visualization and analysis ... and ViTALConnect(R) 4.1. This,comprehensive package offers powerful ...
Cached Biology Technology:Instant JChem 2.0 Released: Instant JChem Personal Free for All Users 2Codexis Appoints Singapore Laboratories Managing Director 2Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 2Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 3Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 4
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... market releases photos and video of the recent opening bell at ... . Gino Pereira , CEO of NXT-ID ... Chad A. Verdi rang the bell.  ... employees "for their work and dedication in bringing the world,s next ...
(Date:10/14/2014)... years since T. rex took its last ... is breathing life back into dinosaurs using high-powered computer ... has important implications for how dinosaurs used their noses ... of smell and cool their brains. , "Dinosaurs ... Jason Bourke, lead author of the new study published ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... Biometric Time Clock Security and ... ATLANTA, Nov. 27 M2SYS Technology, ... that Software,Techniques Inc. has enhanced their TimeKRON ... Bio-SnapON(TM) solution., Bio-SnapON(TM) allows companies to ...
... for High-Performance Notebook Computers ... and Consumer Electronic Applications, SUNNYVALE, ... a leading supplier of innovative computer products including,hard disk ... of its MHZ2 BH series mobile hard disk drive ...
... has both UCLA and a team of enterprising UCLA scientists ... In 1996, a unique collaboration of leading ... company Agensys Inc. and the company now stands to ... making it one of the largest Los Angeles-based private biotech ...
Cached Biology News:Software Techniques Inc. Selects M2SYS Fingerprint Software to Meet Continuous Growth and Demand for Desktop Biometric Time & Attendance Solutions 2Fujitsu Announces Industry Highest Capacity 2.5 Inch SATA Hard Disk Drive at 320GB(1) 2Fujitsu Announces Industry Highest Capacity 2.5 Inch SATA Hard Disk Drive at 320GB(1) 3Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 2Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 3
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Mouse anti-Cytohesin 2, Monoclonal Antibody, Unconjugated ... assay dependent dilution. ICC: Use at an assay ... 5 - 10 ug/ml, this concentration is determined ... molecular weight: 40 kDa. Not tested in other ...
SHP-2 Antibody...
... Glycine Transporter 2, Neuronal (GLYT2). The ... from the central nervous system. The staining ... pattern described using in situ hybridization with ... has been described for glycinergic neurons. Preabsorption ...
Biology Products: